Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

[1]  K. Shimada,et al.  Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009 , 2013, BMC Cancer.

[2]  Y. Homma,et al.  Oncological outcomes of the prostate cancer patients registered in 2004: Report from the Cancer Registration Committee of the JUA , 2011, International journal of urology : official journal of the Japanese Urological Association.

[3]  N. Tanaka,et al.  The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration , 2011, BMC urology.

[4]  P. Unger,et al.  Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. , 2011, The Journal of urology.

[5]  Katsunori Yoshida,et al.  Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. , 2010, Japanese journal of clinical oncology.

[6]  M. Cooperberg,et al.  Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Kuban,et al.  Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? , 2008, International journal of radiation oncology, biology, physics.

[8]  S. Naito,et al.  Japanese Urological Association guidelines on prostate‐specific antigen‐based screening for prostate cancer and the ongoing cluster cohort study in Japan , 2008, International journal of urology : official journal of the Japanese Urological Association.

[9]  M. Cooperberg,et al.  High-risk prostate cancer in the United States, 1990–2007 , 2008, World Journal of Urology.

[10]  H. Akaza,et al.  Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. , 2007, Japanese journal of clinical oncology.

[11]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[12]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[13]  Hiroyuki Fujimoto,et al.  Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association , 2005, International journal of urology : official journal of the Japanese Urological Association.

[14]  M. Cooperberg,et al.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). , 2003, The Journal of urology.

[15]  M. Cooperberg,et al.  Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. , 2003, The Journal of urology.

[16]  Lisa M. Schwartz,et al.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? , 2003, JAMA.

[17]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .